Method of Purification and Properties of Anti-XIa (Inhibitor of the Contact Product)

Summary

1. A normally occurring inhibitor (anti-XIa) of product XIa (contact product, activated PTA) was purified 100-fold by a combination of zinc acetate precipitation, anion exchange chromatography and starch block electrophoresis.

2. The inhibitor was shown by electrophoresis to have the mobility of an alpha globulin. The purified inhibitor was free of antithrombin III activity and anti-XIIa activity. The anti-XIa fraction was free of coagulation factor activity and was stable over a wide range of pH and temperature. Analytical ultracentrifugation of a purified inhibitor fraction showed a symmetrical peak of S_20w = 3.69.

3. The inhibitor was not consumed during its interaction with product XIa.

4. With the use of the purified inhibitor, the product XIa preparation used was shown to be practically free of precursor factor XI or XII activity.

^* Present adress: College of Physicians and Surgeons, Columbia University, New York.

• References

• 1 Bell W. N, Alton H. G. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond.) 174: 880 1954;
• 2 Biggs R, Macfariane R. G. Human blood coagulation and its disorders. 3rd ed.. Blackwell Scientific Publications; Oxford: 1962
• 3 Cohn E. J, Strong L. E, Hughes W. L, Mulford D. J, Ashworth J. N, Melin M, Taylor H. L. Preparation and properties of serum and plasma proteins. IV. A system for the separation of the protein and lipoprotein components of biological tissues and fluids. J. Amer, chem. Soc 05: 459 1946;
• 4 Egeberg O. On the natural blood coagulation inhibitor system. Investigations of inhibitor factors based on anti-thrombin deficient blood. Thrombos. Diathes. haemorrh. (Stuttg.) 14: 473 1965;
• 5 Fahey J. L, McCoy P. F, Goulian M. Chromatography of serum proteins in normal and pathological sera: The distribution of protein bound carbohydrate and cholesterol, sidero-philin, thyroxin binding protein, B₁₂-binding protein, alkaline and acid phosphatases, radio-iodinated albumin and myeloma proteins. J. clin. Invest 37: 272 1958;
• 6 Grabar P, Burtin P. L’Analyse immunoelectrophoretique, ses applications aux liquides biologiques humains. Ed. Masson Paris 1960.
• 7 Iatridis S. G, Ferguson J. H, Iatridis P. G, Mauldin R. Thrombogenic properties of surface factor; evidence for an antisurface factor activity in canine plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 12: 35 1964;
• 8 Iatridis S. G, Iatridis P. G, Ferguson J. H. Roles of surface factor and a plasma inhibitory activity (Anti SF) during experimental thrombosis in rabbits. Thrombos. Diathes. haemorrh. (Stuttg.) 72: 489 1964;
• 9 Jürgens J. Factor VII inhibitor. A new physiological serum accelerator inactivation principle. Acta haemat. (Basel) 14: 57 1955;
• 10 Hensen A, Loeliger E. A. Antithrombin III. Its metabolism and its function in blood coagulation. Thrombos. Diathes. haemorrh. Suppl. 1 ad. Vol. IX (1963).
• 11 Macfariane R. G. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature (Lond.) 202: 498 1964;
• 12 Kekwick R. A, MacKay M. E, Nance M. H, Record B. R. The purification of human fibrinogen. Biochem. J 60: 671 1955;
• 13 Kochwa S, Smith E, Davis B. J, Wasserman L. R. Abnormal proteins and protein fractions in myeloma. N. Y. Acad. Sci 121: 445 1964;
• 14 Margolis J. Initiation of blood coagulation by glass and related surfaces. J. Physiol. (Lond.) 157: 95 1957;
• 15 Michaelis L. Der Acetat-Veronal-Puffer. Biochem. Z 234: 139 1913;
• 16 Nossel H. L. The Contact Phase of Blood Coagulation. Blackwell Scientific Publications; Oxford: 1964
• 17 Nossel H. L, Niemetz J. A normal inhibitor of the blood coagulation contact reaction product. Blood 25: 712 1965;
• 18 Rapaport S. I, Schiffman S, Patch M. J, Ware A. G. A simple specific one stage assay for plasma thromboplastin antecedent activity. J. Lab. clin. Med 57: 771 1961;
• 19 Ratnoff O. D, Davie E. W, Mallett D. L. Studies on the action of Hageman factor : Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest 40: 803 1961;
• 20 Ratnoff O. D, Rosenblum J. M. Role of Hageman factor in the initiation of clotting by glass. Evidence that glass frees Hageman factor from inhibition. Amer. J. Med 25: 160 1958;
• 21 Schmid K, McNair M. B, Burgi A. The chromatographic separation and purification of acidic proteins on carboxylated ion exchange resins. J. biol. Chem 230: 853 1958;
• 22 Soulier J. P, Larrieu M. J. Etude analytique des temps de Quick allonges. Dosages de prothrombine, de proconvertine de pro-accelerine. Sang 23: 549 1952;
• 23 Soulier J. P. Les inhibiteurs naturels de la coagulation. Sang 30: 262 1959;
• 24 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest. II 37 1959
• 25 Wagner R. M, Brannon Jr. W. M, Brinkhous K. M. Anti-accelerator (anticonvertin) activity of canine plasma and serum. Proc. Soc. exp. Biol. (N. Y.) 89: 266 1955;